The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL

Tamer Othman, Aaron C. Logan, Lori Muffly, Jessica Leonard, Jae Park, Bijal Shah, Ibrahim Aldoss

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

CAR T-cell therapy is a recent therapeutic advancement that has transformed the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To date, there are 2 FDA-approved CAR-T products for R/R B-ALL: tisagenlecleucel in patients aged,26 years and brexucabtagene autoleucel in those aged $18 years. This review summarizes the pivotal clinical trials that led to FDA approval of these 2 products and highlight emerging data addressing key questions pertinent to CAR-T utilization in the rapidly evolving landscape of R/R ALL management. These include optimal sequencing of CAR-T among other novel immunotherapeutic agents, the role of consolidation and maintenance following CAR-T, novel CAR-T constructs currently under clinical development, and strategies to optimize use of commercially available CAR-T products to improve patient outcomes.

Original languageEnglish (US)
Article numbere247065
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume22
Issue number8
DOIs
StatePublished - Oct 2024

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL'. Together they form a unique fingerprint.

Cite this